Havrix Monodose (Hepatitis A Virus (Inactivated ) Adsorbed On Aluminium Hydroxide Hydrated Produced On Human Diploid)

Havrix Monodose is indicated for the prevention of hepatitis A infection in individuals who are at risk of exposure. It is commonly used in the following situations:

• Routine immunisation of children and adults living in or travelling to areas with high hepatitis A prevalence.
• Protection of laboratory personnel handling hepatitis A virus specimens.
• Pre‑exposure prophylaxis for travelers to endemic regions.
• Outbreak control in community or institutional settings.
• Immunisation of individuals with chronic liver disease to reduce disease severity.
• Use in persons seeking protection before international travel.

Side effects of Havrix Monodose are generally mild and transient, reflecting the body’s immune response to the vaccine. Serious adverse events are rare but reported.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or malaise.
• Muscle aches.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis).
• Guillain‑Barré syndrome (very rare).
• High fever persisting more than 48 hours.
• Neurological symptoms such as weakness or tingling.
• Persistent joint pain.
• Severe injection‑site reactions (e.g., cellulitis).

Before administering Havrix Monodose, healthcare providers should consider the following precautions:

• Verify that the individual has no known severe allergy to any vaccine component, especially aluminium hydroxide.
• Defer vaccination in persons with acute moderate or severe illness until recovery.
• Use caution in individuals with a history of Guillain‑Barré syndrome.
• Discuss potential risks and benefits with pregnant or breastfeeding women, as safety data are limited.
• Monitor for signs of an allergic reaction for at least 15 minutes post‑injection.
• Ensure proper storage and handling to maintain vaccine potency.

Havrix Monodose may interact with other medications or vaccines, influencing safety or effectiveness.

Avoid

• Simultaneous administration of live viral vaccines (e.g., measles, mumps, rubella) in the same injection site.
• Use of immunosuppressive therapy that may diminish antibody response.

Use with caution

• Concurrent administration of other inactivated vaccines (e.g., influenza) at a different site.
• Antipyretics (acetaminophen, ibuprofen) taken prophylactically, which may modestly reduce immunogenicity.
• Blood products or immunoglobulins given within 3 months before or after vaccination.
• Chronic corticosteroid therapy, which may affect immune response.
• Any medication that alters immune function, requiring clinical judgment.